Table I.

Disease severity of actively induced EAE is reduced by in vivo treatment with soluble OX-40R:Ig and CTLA-4:Ig

Expt.TreatmentaTreatment RegimenMax. Disease Severity Score10-Day Cumulative Disease ScoredEAE Deaths
Expt. 1Day of Diseaseb
n = 3OX-40R:Ig1, 2, 35.322 ± 110/3
(400 μg/day)
n = 3Saline1, 2, 37.348 ± 160/3
Expt. 2Day After Immunizationc
n = 5OX-40R:Ig10, 11, 12, 136.60/5g
(400 μg/day)
n = 5CTLA-4:Ig (400 μg/day)10, 11, 12, 136.20/5g
n = 5OX-40R:Ig+ CTLA-4:Ig (200 μg+ 200 μg/day)10, 11, 12, 135.80/5g
n = 5Saline10, 11, 12, 138.8NAe4/5f
Expt. 3Day of Diseaseb
n = 6OX-40R:Ig (400 μg/day)1, 2, 3, 4, 56.30/6
n = 6Hu-IgG (400 μg/day)1, 2, 3, 4, 58.5NAe3/6f
  • a OX-40R:Ig, CTLA-4:Ig, and Hu IgG were diluted in sterile saline at the appropriate concentration to deliver the indicated amount in 0.2 ml of saline (i.p. injection).

  • b At the first sign of actively induced EAE, animals were paired according to clinical disease score and then split equally between the two treatment groups. Groups were then treated as indicated.

  • c Animals were randomly assigned to individual treatment groups on day 10 after immunization before disease onset. Groups were then treated as indicated.

  • d The 10-day cumulative disease score is determined by adding the daily clinical disease score of an individual animal for the first 10 days of disease.

  • e Not applicable because not all animals survived to day 10 of disease.

  • f Animals died of disease despite receiving gelatin squares and daily injections of saline alone or as a diluent of Hu IgG.

  • g Significant relative to saline treatment group (p = 0.03), as determined by comparison of proportions.